BeiGene
BGNE
$150.09
Share price
4.14%
Change (1 day)
-41.69%
Change (1 year)
Categories
BeiGene is a Chinese pharmaceutical company engaged in the R&D, and commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.
BeiGene (BGNE) - P/B ratio
P/B ratio as of April 2024 : 4.40
According to BeiGene
's latest financial reports the company has a price-to-book ratio of 4.40.
The price-to-book ratio is a way to measure how much the stock market thinks a company is worth compared to how much the company says its assets are worth on paper.
BeiGene - P/B ratio (from 2016 to 2023)
P/B ratio by year
| Year | P/B ratio | Change |
|---|---|---|
| 2023-12-31 | 5.60 | 4.67% |
| 2022-12-31 | 5.35 | 19.41% |
| 2021-12-31 | 4.48 | -27.83% |
| 2020-12-31 | 6.21 | -40.94% |
| 2019-12-31 | 10.5 | 121.26% |
| 2018-12-31 | 4.75 | -26.93% |
| 2017-12-31 | 6.50 | 90.55% |
| 2016-12-31 | 3.41 | |
| 2015-12-31 | N/A | |
| 2014-12-31 | N/A |
P/B ratio for similar companies or competitors
| Company | P/B ratio | differencediff. | Country |
|---|---|---|---|
 OPKO Health
OPK | 0.6171 | -85.96% | 🇺🇸 USA |
 Onconova Therapeutics ONTX | 1.44 | -67.24% | 🇺🇸 USA |